Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Intangibles (2022)

NewAmsterdam Pharma (NAMS) has disclosed Intangibles for 1 consecutive years, with $84.8 million as the latest value for Q4 2022.

  • Quarterly Intangibles changed N/A to $84.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $84.8 million through Dec 2022, changed N/A year-over-year, with the annual reading at $84.8 million for FY2022, N/A changed from the prior year.
  • Intangibles hit $84.8 million in Q4 2022 for NewAmsterdam Pharma.
  • In the past five years, Intangibles ranged from a high of $84.8 million in Q4 2022 to a low of $84.8 million in Q4 2022.